Combination chemotherapy for advanced colorectal cancer. A pilot study

Area of Science:

• Oncology
• Medical Oncology
• Cancer Research

Background:

• Advanced colorectal carcinoma often presents with widespread metastases.
• Standard chemotherapy regimens have limitations in efficacy and toxicity.
• The potential synergistic effects of drug combinations require investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel combination chemotherapy regimen in patients with advanced colorectal carcinoma.
• To explore the hypothesis that cisplatinum can potentiate the antitumor activity of other chemotherapeutic agents.

Main Methods:

• A cohort of 23 patients with advanced colorectal carcinoma, including those with liver and lung metastases, received mitomycin-C, vincristine, cisplatinum, and 5-fluorouracil.
• Treatment involved specific intravenous dosages and infusion schedules over defined intervals.
• Prior chemotherapy or radiotherapy exposure was noted in a subset of patients.

Main Results:

• An overall response rate of 48% was observed, with one complete response and 10 partial responses.
• The treatment regimen demonstrated manageable toxicity.
• The study provides preliminary evidence for the potential of cisplatinum to enhance chemotherapy efficacy.

Conclusions:

• The combination of mitomycin-C, vincristine, cisplatinum, and 5-fluorouracil shows promising activity in advanced colorectal cancer.
• Cisplatinum may potentiate the antitumor effects of antimetabolites and alkylating agents in this context.
• Further research is warranted to confirm these findings and optimize treatment strategies.